Navigation Links
Arpida Interim Results for six Months to 30 June 2007
Date:8/28/2007

SSI.

With a view to a potential launch of intravenous iclaprim in 2008, we are significantly expanding our medical and scientific communications. A total of 24 abstracts on iclaprim have been accepted at the upcoming ICAAC and IDSA conferences in the USA. We are eager to share our preclinical and clinical data with the medical and scientific community.

Dr Islam added: Progress was not limited to our most advanced programme, but was seen across the board. It included the authorisation from the US FDA to initiate Phase II trials with intravenous iclaprim in hospital-acquired pneumonia, as well as steady progress in other programmes such as oral iclaprim, AR-709 and AR-2474. Looking at the disturbing increase and the broadening of bacterial resistance against many of the current drugs, I feel these antibiotic programmes are aimed at significant existing or emerging medical needs.

Very recently, we succeeded in broadening our clinical pipeline further by acquiring the late-stage anti-fungal TLT therapy. TLT is about to enter Phase III clinical trials in Europe targeting onychomycosis an important indication, affecting dozens of millions of people worldwide.

Dr Islam concluded: Overall I can say that Arpida remains on a steady, successful course, strengthening the foundations for a profitable future.

Financial review for six months to 30 June 2007

Key financial indicators

(CHF million) 2007 H1 2006 H2 2006 H1

Research and development expenses (27.7) (40.8) (23.9)

Management and general expenses (6.0) (4.6) (4.6)

Total operating expenses (33.7) (45.4) (28.5)

Net result (33.8) (44.6) (27.9)

Cash and financial investments end of 94.7 72.8 98.6

period

Equity end of period 87.7 65.5 104.9

Res
'/>"/>

SOURCE Arpida
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Effects of Thermal Cycler Well-To-Well Temperature Uniformity on PCR Results
2. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
3. Achieving Reliable Protein Quantitation Results Using ICAT Reagents, MALDITOF Mass Spectrometry, and Advanced Data Interpretation Tool
4. How Best Buy said bye to burnout, hello to results
5. Economic survey reveals better 2006 results
6. Third Wave Reports Third-Quarter Financial Results
7. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
8. Midwest small-cap life sciences turn in mixed third-quarter results
9. To boost advertising results, consider improving your web site
10. RedPrairie Reports Strong Results
11. 2003 Biotech Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City Animal ... and animal health companies to hear from animal health companies with the newest ... received licensing agreements or distribution contracts. This meeting is one of the ...
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... two investor conferences in the month of September.  ... Officer, will present at Rodman & Renshaw,s 17th Annual ... 10:25am ET/7:25am PT at the St. Regis Hotel in ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER ... expertly narrows down the product choices to a manageable shortlist of bench and ... list to models that fit best with the customer’s industry and application. ...
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2METTLER TOLEDO Updates Online Scale Selection Tool 2
... at Northwestern Universitys Center for Quantum Devices (CQD) ... detecting single photons in the ultraviolet region (360-200 ... only available technology in the short wavelength UV ... detection sensitivity. However, these fragile vacuum tube devices ...
... published,"Thought Leader Insight & Analysis: Alzheimer,s Disease," designed ... companies with a,stake in the market for diagnostics ... the size of this patient population and the ... is not surprising to see the,large number of ...
... Better Option for Humans, EGG HARBOR TOWNSHIP, ... first time, The British Institute of Homeopathy, U.S.A. ... U.S. medical and,homeopathic practitioners for a low-introductory cost ... therapy is more advantageous because,it does not carry ...
Cached Biology Technology:Tiny avalanche photodiode detects single UV photons 2New Report Tackles the Changing Landscape for Alzheimer's Diagnostics and Treatments 2
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... at the American College of Cardiology's 55th Annual Scientific ... cholesterol lowering with a statin drug can regress (partially ... , This finding has never before been ... commonly used cholesterol lowering treatment. Previous research had indicated ...
... clinical research is being done, warns a senior doctor ... is failing patients and clinicians by neglecting this vital ... information that doctors need to diagnose and treat patients ... field of neurology alone, many examples exist where a ...
... new study by Rebecca Baggaley, Neil Ferguson, and Geoff ... epidemic in poor countries will not be controlled through ... As they demonstrate in an article in the open-access ... such as counseling patients and their communities about safe ...
Cached Biology News:Intensive statin therapy may partially reverse plaque build-up in arteries 2Access to antiretrovirals unlikely to reduce HIV infection rates 2
The 12-Tube Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 12 microcentrifuge tubes. ,Magnets: Neodymium rare earth permanent ma...
DONOR BOVINE SERUM AND PLASMA...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
...
Biology Products: